Genetics, one of the keys to the prognosis of progression of osteoarthritis.

-Bioiberica leads the project Arthrosischip to predict the evolution of the osteoarthritis of knee with an analysis of saliva

-Francisco j. Blanco Garcia, rheumatologist complex Hospitalario Universitario A Coruña, has presented at the OARSI databases of research, with the collaboration of 32 hospital centres of all Spain

Barcelona, 2011-September the study of the genetics of arthritis offers new fields of research on the forecast and the progression of osteoarthritis of the knee. So this weekend in arthrosis OARSI World Congress, held in San Diego (California), in which Bioiberica has introduced the Arthrosischip to predict the evolution of arthritis from a saliva sample has been exposed.

Arthritis is a disease with a strong genetic component in its development and progression. On some problems of osteoarthritis, genetic inheritance reaches between 60% and 70% of cases. This evidence has laid the basis of the investigation led by Bioiberica and expounded by Dr. Francisco j. Blanco, rheumatologist of the complex Hospitalario Universitario A Coruña, in the World Congress of osteoarthritis.

Dr. Francisco j. Blanco explained that arthritis is a poligenética disease with multiple interactions between genes. He also mentioned that genetic material can be found in the nucleus of the condrocitos both mitochondria and that such genetic material plays an important role in the development of the disease. In this way, different mitochondrial DNA haplogroups may have different phenotypes artrósicos and
probability of progression.

On the basis of these claims is developing the project Arthrosischip, to create a tool that combines clinical and genetic data (DNA chip) allowing to predict the progression of primary osteoarthritis of the knee in patients previously diagnosed the disease and to customize your treatment as well as predict the risk of implantation of prosthesis in such patients. Based on the technology of DNA microarrays, Arthrosischip shall consist of a genetic analysis from a saliva sample that could identify those genetic mutations associated with the progression of arthritis that are significant and clinical data, basically, risk factors such as sexthe IMC or concomitant diseases such as diabetes. Dr. White also explained the design of the trial (multicenter retrospective) which is currently in the final stage of the recruitment of samples.

It is a study jointly developed between Bioiberica, company with more than 30 years of experience in health of joints and leader in chondroprotection, and Progenika, specialist in the design and development of tools for personalized medicine. In it, involved 32 hospital centres of all Spain.

The OARSI in Barcelona in April 2012

With Bioiberica as one of the major sponsors, the next edition of OARSI will take place in Barcelona in April. During these days will gather in the city more than one thousand of specialists from around the world, including rheumatologists, researchers, orthopaedic surgeons, radiologists, clinical and other stakeholders in the research of arthritis. However, this Congress has the most prestigious professionals dedicated to the treatment of arthritis to share progress and experiences in the investigation of this disease. Why Barcelona and Spain will become one week the world headquarters of arthritis.

Bioiberica Farma

Bioiberica Farma is the only Spanish laboratory specializing in research and development of effective drugs for the treatment of osteoarthritis. Specifically, specialises in chondroprotection, namely, prevention, diagnosis and treatment of cartilage, synovial membrane, and the subcondral bone injuries.

This expertise in the treatment of osteoarthritis has helped Bioiberica Farma occupies a leading position endorsed by numerous published clinical trials, research projects underway, the recognition of different societies scientific and medical, strict quality control chemical and biological production processes, the quality of their products and editing of publications specialised in chondroprotection.